Cargando…

Why restricted mean survival time methods are especially useful for non-inferiority trials

Detalles Bibliográficos
Autores principales:	Quartagno, Matteo, Morris, Tim P, White, Ian R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592094/ https://www.ncbi.nlm.nih.gov/pubmed/34553627 http://dx.doi.org/10.1177/17407745211045124

Ejemplares similares

A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials
por: Quartagno, Matteo, et al.
Publicado: (2023)

The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial
por: Quartagno, Matteo, et al.
Publicado: (2023)

Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
por: Quartagno, Matteo, et al.
Publicado: (2020)

Analysis of the Single Ventricle Reconstruction Trial Using Restricted Mean Survival Time and Shunt Type Received
por: Dolgner, Stephen J., et al.
Publicado: (2022)

Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia
por: Kim, Dae Hyun, et al.
Publicado: (2021)

Choosing and changing the analysis scale in non-inferiority trials with a binary outcome
por: Li, Zhong, et al.
Publicado: (2021)

The Fight for Digital Sovereignty: What It Is, and Why It Matters, Especially for the EU
por: Floridi, Luciano
Publicado: (2020)

Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data
por: Huang, Qiao, et al.
Publicado: (2022)

Assessment of Median and Mean Survival Time in Cancer Clinical Trials
por: Das, Ananya, et al.
Publicado: (2023)

Rethinking non-inferiority: a practical trial design for optimising treatment duration
por: Quartagno, Matteo, et al.
Publicado: (2018)

Restricted mean survival time regression model with time‐dependent covariates
por: Zhang, Chengfeng, et al.
Publicado: (2022)

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
por: Karrison, Theodore, et al.
Publicado: (2018)

Estimation of Heterogeneous Restricted Mean Survival Time Using Random Forest
por: Liu, Mingyang, et al.
Publicado: (2021)

Omnibus test for restricted mean survival time based on influence function
por: Gu, Jiaqi, et al.
Publicado: (2023)

Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers
por: Han, Kyunghwa, et al.
Publicado: (2022)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis
por: Lueza, Béranger, et al.
Publicado: (2016)

Analyzing differences between restricted mean survival time curves using pseudo-values
por: Ambrogi, Federico, et al.
Publicado: (2022)

Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators
por: Nemes, Szilárd, et al.
Publicado: (2022)

Refining the Association Between Body Mass Index and Atrial Fibrillation: G‐Formula and Restricted Mean Survival Times
por: Conner, Sarah C., et al.
Publicado: (2019)

Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost
por: Wu, Hongji, et al.
Publicado: (2021)

What matters, most-especially now?
por: Kampmann, Beate
Publicado: (2020)

I will survive: why peer should not rhyme with fear
por: John, M
Publicado: (2013)

Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis
por: Lueza, Béranger, et al.
Publicado: (2016)

Restricted Mean Survival Time in Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure
por: Shi, Sandra, et al.
Publicado: (2020)

Metformin improves survival in intensive care unit patients, but why?
por: Riksen, Niels P, et al.
Publicado: (2013)

Why coronavirus survives longer on impermeable than porous surfaces
por: Chatterjee, Sanghamitro, et al.
Publicado: (2021)

We Can Do Better: Why Pastoral Care Visitation to Hospitals is Essential, Especially in Times of Crisis
por: Hall, Daniel E.
Publicado: (2020)

The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics
por: Quartagno, Matteo, et al.
Publicado: (2020)

Optimal two-stage designs based on restricted mean survival time for a single-arm study
por: Shan, Guogen
Publicado: (2021)

Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022)

Understanding the null hypothesis (H(0)) in non-inferiority trials
por: Mallat, Jihad
Publicado: (2017)

Tuning multiple imputation by predictive mean matching and local residual draws
por: Morris, Tim P, et al.
Publicado: (2014)

Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals
por: Rehal, Sunita, et al.
Publicado: (2016)

An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use
por: Calkins, Keri L., et al.
Publicado: (2018)

Restricted mean survival time of older adults with severe aortic stenosis referred for transcatheter aortic valve replacement
por: Rodighiero, Julia, et al.
Publicado: (2020)

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies
por: Messori, Andrea, et al.
Publicado: (2021)

Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models
por: Mozumder, Sarwar I., et al.
Publicado: (2021)

Response to: Understanding the null hypothesis (H0) in non-inferiority trials
por: Zhou, Xiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0t4p2rujbsef7496v5cm2qu07o